Skip Navigation


European Heart Journal Advance Access originally published online on April 10, 2009
European Heart Journal 2009 30(10):1164-1166; doi:10.1093/eurheartj/ehp155
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
30/10/1164    most recent
ehp155v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Staessen, J. A.
Right arrow Articles by Birkenhäger, W. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Staessen, J. A.
Right arrow Articles by Birkenhäger, W. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

Candesartan for cardiovascular prevention in Japanese hypertensive patients with coronary heart disease

Jan A. Staessen1,2,*, Tom Richart2 and Willem H. Birkenhäger3

1 Department of Epidemiology, Maastricht University, The Netherlands
2 Studies Coordinating Centre, Division of Hypertension and Cardiovascular Rehabilitation, Department of Cardiovascular Diseases, University of Leuven, Leuven, Belgium
3 Erasmus University, Rotterdam, The Netherlands

* Corresponding author. Tel: +31 43 388 2374, Fax: +31 43 388 4128, Email: ja.staessen@epid.unimaas.nl

This editorial refers to ‘Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary heart disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE)’{dagger}, by H. Kasanuki et al., on page 1203

The first 10% of the full text of this article appears below.

In the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Heart Disease (HIJ-CREATE),1 Kasanuki and colleagues randomized hypertensive patients with angiographically proven coronary heart disease either to candesartan or to blood pressure-lowering treatment not based on an angiotensin II type-1 receptor blocker (ARB), but possibly including an angiotensin-converting enzyme inhibitor (ACEI). The primary endpoint was the incidence of major cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, heart failure, stroke, and other cardiovascular events requiring hospitalization. During a median follow-up of 4.2 years, 264 patients of the candesartan group (25.8%) and 288 of the non-ARB group (28.1%) experienced an event. Neither for the composite primary endpoint [hazard ratio 0.89, 95% confidence interval (CI) 0.76–1.06) nor for any of its components did the hazard ratios comparing candesartan with non-ARB treatment approach . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE)
Hiroshi Kasanuki, Nobuhisa Hagiwara, Saichi Hosoda, Tetsuya Sumiyoshi, Takashi Honda, Kazuo Haze, Michitaka Nagashima, Jun-ichi Yamaguchi, Hideki Origasa, Mitsuyoshi Urashima, Hiroshi Ogawa, and for the HIJ-CREATE Investigators
EHJ 2009 30: 1203-1212. [Abstract] [Full Text]